ACADIA Pharmaceuticals Inc. Stock Upgraded (ACAD)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- ACADIA Pharmaceuticals (Nasdaq: ACAD) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, poor profit margins and disappointing return on equity.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • ACAD's very impressive revenue growth greatly exceeded the industry average of 5.4%. Since the same quarter one year prior, revenues leaped by 495.5%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • ACAD's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels.
  • ACADIA PHARMACEUTICALS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ACADIA PHARMACEUTICALS INC swung to a loss, reporting -$0.44 versus $0.38 in the prior year. This year, the market expects an improvement in earnings (-$0.37 versus -$0.44).
  • The gross profit margin for ACADIA PHARMACEUTICALS INC is currently extremely low, coming in at 10.50%. Despite the low profit margin, it has increased significantly from the same period last year. Despite the mixed results of the gross profit margin, ACAD's net profit margin of -69.10% significantly underperformed when compared to the industry average.
  • Net operating cash flow has decreased to -$5.31 million or 27.18% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a P/E ratio of -6.4, below the S&P 500 P/E ratio of 17.7. ACADIA has a market cap of $130.2 million and is part of the health care sector and drugs industry. Shares are up 113% year to date as of the close of trading on Wednesday.

You can view the full ACADIA Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

3 Housing Plays With Solid Earnings

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon